Financial Performance - The company's operating revenue for Q1 2025 was CNY 876,077,751.32, a decrease of 1.63% compared to CNY 890,636,572.78 in the same period last year[4] - Net profit attributable to shareholders was CNY 50,711,565.71, down 14.10% from CNY 59,036,697.53 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.05, representing a decrease of 16.67% from CNY 0.06 in the same period last year[4] - The weighted average return on equity was 1.23%, down 0.23 percentage points from 1.46% year-on-year[4] - Net profit for Q1 2025 was CNY 63,048,460.18, a decline of 13.68% from CNY 73,042,414.08 in Q1 2024[18] - Earnings per share for Q1 2025 was CNY 0.05, compared to CNY 0.06 in Q1 2024[19] Cash Flow - The net cash flow from operating activities was negative CNY 117,523,249.20, a decline of 410.41% compared to a positive CNY 37,860,668.63 in the previous year[4] - Cash inflow from financing activities in Q1 2025 was 78,000,000.00, an increase from 57,000,000.00 in Q1 2024[21] - The net cash flow from financing activities improved to 36,049,533.40 in Q1 2025, compared to -1,534,251,586.89 in Q1 2024[21] - The cash and cash equivalents at the end of Q1 2025 were 2,690,022,771.99, down from 3,190,395,526.72 in Q1 2024[21] - The cash inflow from the disposal of subsidiaries and other business units in Q1 2024 was 2,950,572,349.92, which is not reported for Q1 2025[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,044,055,077.03, an increase of 0.73% from CNY 6,000,330,923.23 at the end of the previous year[4] - Total assets and equity as of March 31, 2025, were CNY 6,044,055,077.03 and CNY 4,851,414,184.27 respectively, showing slight increases from CNY 6,000,330,923.23 and CNY 4,788,365,724.09 as of December 31, 2024[16] - The company's current assets totaled 4.186 billion RMB, showing an increase from 4.144 billion RMB at the end of 2024[14] - Total liabilities and equity as of March 31, 2025, were CNY 6,044,055,077.03, compared to CNY 6,000,330,923.23 at the end of 2024[16] Research and Development - The company reported a significant increase in R&D expenses, contributing to the decline in net profit and earnings per share[5] - Research and development expenses for Q1 2025 were CNY 41,789,315.57, up 27% from CNY 32,891,611.79 in Q1 2024[17] - The company launched 47 new products and obtained 12 new patents in the cosmetics sector, focusing on R&D and technological innovation[10] Revenue by Segment - The cosmetics segment generated 526 million RMB in revenue with a gross margin of 61.06%, while the Yilian brand and Aier Doctor brand contributed 250 million RMB and 236 million RMB, respectively[10] - The pharmaceutical segment reported revenue of 108 million RMB with a gross margin of 54.80%, and successfully launched 2 functional beverages during the reporting period[11] - The raw materials and additives segment generated 86 million RMB in revenue with a gross margin of 39.54%, and the sales of hyaluronic acid raw materials increased by 32% year-on-year[12] Other Financial Metrics - Non-operating income included government subsidies amounting to CNY 8,842,888.23, impacting the overall financial performance positively[8] - The major reasons for the decline in net profit included reduced revenue, decreased profits from associated companies, and increased R&D investments[5] - The company experienced a decrease in sales expenses, which were CNY 310,926,503.36 in Q1 2025, down from CNY 322,975,649.96 in Q1 2024[17] - The company paid 29,500,000.00 for debt repayment in Q1 2025, significantly lower than 1,571,450,000.00 in Q1 2024[21] - The company did not apply new accounting standards starting from 2025[21]

证券代码：600223 证券简称：福瑞达 编号：临 2025-013 鲁商福瑞达医药股份有限公司 关于 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将鲁商福瑞达医药股份有限公司（以下 简称"公司"）2025 年第一季度主要经营数据披露如下： 一、2025 年第一季度公司主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（件） | 销量（件） | 营业收入（元） | | --- | --- | --- | --- | | 护肤类 | 25,224,291.90 | 26,608,754.90 | 526,345,075.93 | 二、2025 年第一季度公司主要产品和原材料的价格变动情况 护肤类产品 2025 年第一季度平均售价同比下降 0.75%。 （二）主要原材料价格波动情况 公司主要原材料有包装物、保湿剂、活性物、乳化剂、油脂等。 1、包装物 2025 年第一季 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-014 鲁商福瑞达医药股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2025 年 4 月 28 日（星期一）至 5 月 7 日 （星期三）16:00 前将需要了解的情况和相关问题通过电子邮件的形式发送至公 司投资者关系邮箱：lsfrd600223@163.com。公司将在业绩说明会上对投资者普 遍关注的问题进行回答。 鲁商福瑞达医药股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日披露 公司 2025 年第一季度报告，为了便于广大投资者更全面深入地了解公司 2025 年第一季度业绩和经营情况，公司拟于 2025 年 5 月 8 日（星期四）15:00-16:00 举行 2025 年第一季度业绩说明会，就投资者普遍关心的问题进行交流。 一、业绩说明会类型 本次投资者说明会以网络文字互动的形式召开，公司将针对 2025 年第一季 度业绩和经营情况 ...

Group 1: Financial Performance - In Q1 2025, the company achieved operating revenue of 876 million yuan and a net profit attributable to the parent company of 51 million yuan [1] - As of March 31, 2025, total assets amounted to 6.044 billion yuan, with net assets attributable to the parent company at 4.156 billion yuan [1] Group 2: Cosmetics Business - The cosmetics segment generated operating revenue of 526 million yuan in Q1, with a gross margin of 61.06% [1] - The Yilian brand experienced significant growth, with Q1 revenue of 250 million yuan, representing a 25% year-on-year increase [1] - The Yilian spray product line announced a new spokesperson, Zhang Linghe, leading to a 69% increase in sales [1] - The focus on the "Pongrun" cream as a core product resulted in a 65% year-on-year increase in sales for the Pongrun water and milk products [1] - The Aier Doctor brand accelerated its brand adjustment, achieving Q1 revenue of 236 million yuan [1] - The Aier Doctor brand launched new products, including a "probiotic special gift box" and a new cleansing product [1] - The Kemi brand focused on "collagen anti-aging" and implemented a strategy centered on collagen products, ranking first in popularity on Douyin for collagen essence [1] Group 3: Pharmaceutical Business - The pharmaceutical segment maintained stable performance with operating revenue of 108 million yuan and a gross margin of 54.80% [2] - The company continued to advance drug research and development, launching two functional beverages during the reporting period [2] - Organizational changes were made to adapt to market policy changes, including the establishment of a KA sales department and a digital marketing department [2] - The company developed 200 new clients in hospital and OTC channels [2] Group 4: Raw Materials and Additives - The raw materials and additives segment achieved operating revenue of 86 million yuan with a gross margin of 39.54% [2] - The raw materials segment focused on technological innovation, obtaining two new authorized invention patents [2] - The company established a national-level postdoctoral research workstation and progressed with domestic and international pharmaceutical-grade project applications [2] - The sales of hyaluronic acid raw materials increased by 32% year-on-year, with an 11 percentage point increase in gross margin [2]

| 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0500 | 0.0600 | -16.67 | 0.1300 | | 每股净资产（元） | 4.09 | 4.01 | 2 | 3.78 | | 每股公积金(元) | 0.6 | 0.6 | 0 | 0.61 | | 每股未分配利润(元) | 2.22 | 2.16 | 2.78 | 1.99 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 8.76 | 8.91 | -1.68 | 12.72 | | 净利润(亿元) | 0.51 | 0.59 | -13.56 | 1.29 | | 净资产收益率(%) | 1.23 | 1.46 | -15.75 | 3.42 | 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 三、分红送配方案情况 本次公司不分配不转赠。 前十大流通股东累计持有： 59963.59万股， ...

福瑞达（600223）公告，2025年第一季度营收为8.76亿元，同比下降1.63%；净利润为5071.16万元，同 比下降14.10%。 ...

金融界 2025 年 4 月 24 日消息，国家知识产权局信息显示，深圳市福瑞达科技有限公司取得一项名 为"一种汽车用电池管理系统的唤醒回采电路"的专利，授权公告号 CN222784789U，申请日期为 2024 年 6 月。 专利摘要显示，本实用新型公开了一种汽车用电池管理系统的唤醒回采电路，包括微控制器、CAN 总 线收发器、电源开关，所述 CAN 总线收发器采集汽车 BMS 相关信息，并将相关信息传输给微控制 器，实现 CAN 总线收发器与微控制器电连接进行数据传输和回采，电源开关通过 VBAT 接口连接到电 池，电源开关通过 EN 引脚控制开闭状态，当 EN 引脚被拉高时，电源开关打开，使 VBAT 电压能够流 向系统，电源开关通过 Q2 引脚输出用于驱动其他负载，CAN 总线收发器的 RxD 引脚和 TxD 引脚分别 与微控制器的 IN 引脚和 Out 引脚电连接，VBAT 接口电连接一个二极管 D1、一个电阻 R3、一个电阻 R2 后电连接 CAN 总线收发器的 WAKE 接口。 天眼查资料显示，深圳市福瑞达科技有限公司，成立于2016年，位于深圳市，是一家以从事计算机、通 信和其他电子设备制造业 ...

皮肤衰老的本质，是胶原纤维网的崩塌。但如何让外源性胶原穿透角质层这座"铜墙铁壁"，始 终是行业难题。消费者一边为"胶原流失"焦虑，一边质疑涂抹产品的实际功效——分子量超过 5 0 0道尔顿的胶原蛋白真能渗透吗？活性成分会被皮肤"拒之门外"吗？ 2 0 2 5 年 4 月 ， 福 瑞 达 生 物 股 份 旗 下 珂 谧 在 济 南 召 开 的 " 2 0 2 5 重 组 胶 原 蛋 白 技 术 发 布 会 暨 珂 谧 Ke y C穿膜胶原新品首发式"上，给出了一个颠覆性答案。 这场以"穿膜胶原"为核心的技术革命，不仅将胶原透皮效率提升2 7 . 5倍，更让中国美妆科技首 次 站 上 全 球 抗 衰 技 术 竞 争 的 制 高 点 。 这 场 突 破 背 后 ， 是 科 研 逻 辑 的 颠 覆 ， 还 是 产 业 格 局 的 重 构？ 皮肤角质层的屏障功能，曾被视作大分子胶原的"天堑"。 传统透皮法则认为，分子量超过5 0 0道尔顿的成分难以穿透角质层。但福瑞达生物股份科研团 队选择了一条反直觉的技术路径—— 不是缩小分子量，而是给胶原装上"穿膜引擎" 。这场看 似违背常识的技术突围，实则是一场从基因设计到分子工 ...

Summary of Conference Call Records Company and Industry Overview - The conference call primarily discusses a pharmaceutical and cosmetics company, focusing on its performance in the healthcare and beauty sectors, including revenue growth, product innovation, and market strategies. Key Points and Arguments Financial Performance - The company achieved an annual revenue of 3.983 billion yuan, with a net profit of 244 million yuan, despite challenges from the real estate sector [1] - Excluding the impact of real estate, the overall business and core products are expected to see a year-on-year profit growth of 54.54% in 2024 compared to 2023 [1] - The Huaron segment reported a revenue of 2.475 billion yuan in 2024, reflecting a year-on-year increase of 2.46% [1] Shareholder Returns - The company distributed a total cash dividend of 112 million yuan, accounting for 45.92% of the annual net profit [2] - The Huaron segment's revenue for the year was 963 million yuan, a growth of 12.36% year-on-year [2] Product Innovation and R&D - The company is focusing on R&D, with significant investments in new product development, including 140 new products launched and breakthroughs in synthetic biology and biomanufacturing technologies [3] - The introduction of new raw materials, such as hyaluronic acid and recombinant proteins, is expected to enhance product offerings and market competitiveness [4] Market Strategy and Expansion - The company is expanding its offline presence, with over 5,000 self-operated and franchise stores, while also enhancing online sales through platforms like Tmall and Douyin [2][8] - The focus on high-end markets and international expansion is evident, with plans to deepen collaborations with brands in non-EU and non-US regions [5] Challenges and Adjustments - The company faced intense competition in the cosmetics sector, leading to adjustments in marketing strategies and product offerings [9][10] - The management acknowledged the need for strategic adjustments in response to market dynamics, particularly in the face of declining growth rates in certain product lines [10][11] Future Outlook - The company aims to continue leveraging technology and brand upgrades to create sustainable value for shareholders, with a focus on a comprehensive industry chain layout [6] - Plans for 2025 include further development of innovative products and enhancing the brand's market positioning [6] Additional Insights - The company is exploring potential mergers and acquisitions to bolster its market position, given its strong cash reserves [47] - The management emphasized the importance of maintaining a balance between defensive and offensive strategies in the current market environment [26] Other Important but Overlooked Content - The company is actively engaging in discussions about the competitive landscape in the beauty sector, particularly regarding the differentiation of its products in the collagen protein market [37] - There is a focus on enhancing the customer experience through AI-driven strategies and optimizing the supply chain for better efficiency [25][44] This summary encapsulates the key insights from the conference call, highlighting the company's financial performance, strategic initiatives, and future outlook in the pharmaceutical and cosmetics industries.

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report emphasizes the ongoing impact of tariff shocks and suggests focusing on high-quality retail channels and differentiated consumer brands that cater to domestic demand [4][22] - The report highlights the transformation of traditional retail, with Yonghui Supermarket leading the way in adapting to a consumer-centric retail era [4][22] - The rise of domestic brands and the recovery of consumer demand are seen as inevitable trends, with recommendations to focus on quality retail channels and differentiated brands [4][22] Summary by Sections Retail Market Review - The retail industry index rose by 2.88% during the week of April 7 to April 11, outperforming the Shanghai Composite Index, which fell by 3.11% [6][13] - The supermarket sector showed the largest increase, with a weekly rise of 13.54% [14][17] - Notable individual stock performances included Guofang Group (+61.1%), Eurasia Group (+26.3%), and Nanning Department Store (+22.4%) [19][20] Industry Dynamics - Yonghui Supermarket has opened a "green channel" for domestic manufacturers affected by export restrictions, receiving over 100 cooperation requests from various sectors [4][22] - The report discusses the approval of a new collagen product by Jinbo Bio, which is expected to strengthen its leading position in the medical beauty sector [4][23] Investment Recommendations - Investment focus areas include: - Traditional retail: Highlighting companies like Yonghui Supermarket and Aiyingshi that are adapting to consumer trends [7][27] - Gold and jewelry: Recommendations for brands like Laopu Gold and Chaohongji that possess differentiated product capabilities [7][28] - Cosmetics: Emphasizing domestic brands such as Maogeping and Shangmei that are expanding into high-potential segments [7][28] - Medical aesthetics: Focusing on companies like Aimeike and Kedi that are positioned to benefit from the recovery in medical beauty consumption [7][28] Company-Specific Insights - Laopu Gold reported a revenue of 8.506 billion yuan (+167.5%) and a net profit of 1.473 billion yuan (+253.9%) for FY2024, indicating strong growth potential [29] - Yonghui Supermarket's revenue for the first three quarters of 2024 was 54.549 billion yuan (-12.1%), with a net loss of 78 million yuan, but it is undergoing significant transformation [32] - Jinbo Bio's new collagen product is expected to provide both immediate filling effects and stimulate collagen regeneration, enhancing its competitive edge in the market [23][24]